HomepageNews
2026.02.26
Recently, the Center for Drug Reevaluation, NMPA and the National Center for ADR Monitoring, China issued a commendation to units with outstanding performance in 2025. JumpCan Pharmaceutical Group was awarded the title of "Outstanding Enterprise for Drug, Device and Cosmetic Adverse Reaction Monitoring and Evaluation Work in 2025" in recognition of its excellent performance in adverse drug reaction monitoring and evaluation.
JumpCan Pharmaceutical has always adhered to the bottom line of drug safety, building a comprehensive quality management system, continuously strengthening full lifecycle drug safety management, further improving of its pharmacovigilance system, and ensuring the safe and rational use of drugs by patients. This recognition signifies the high degree of acknowledgment by the national regulatory authority of the professionalism, standardization, and effectiveness of JumpCan Pharmaceutical's pharmacovigilance system, demonstrating the solid implementation of its responsibilities as a Marketing Authorization Holder (MAH).
Going forward, JumpCan Pharmaceutical will continue to uphold a patient-centered approach, convert this recognition into motivation, use high-quality pharmacovigilance work to promote sustainable corporate development, fulfill its social responsibilities as a listed company, and safeguard public medication safety.
Source: National Center for ADR Monitoring, China "Notice of Commendation for Outstanding Units in the 2025 National Drug, Device and Cosmetic Adverse Reaction Monitoring and Evaluation Work" (Monitoring and Evaluation Office [2026] No. 2)